As obesity and overweight have been demonstrated to be independently associated with a higher risk of cardiotoxicity derived from anthracycline treatment (pooled odds ratio 1.38 (95% CI, 1.06 to 1.80)), patients administered with GnRH analogues should be closely monitored for prevention and prompt management of weight gain. This evidence concerns the gene GNRH1 and Obesity.